Changes in Beneficial Ownership · 4
Kodiak Sciences Inc
KODNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-10262026_091054.xml
Filing details
- Report period
- 2026-10-23
- Issuer
- Kodiak Sciences Inc.
- Issuer CIK
- 0001468748
- Trading symbol
- KOD
Reporting owner 1
- Name
- Yang Taiyin
- Reporting owner CIK
- 0001334505
- Relationship
- Director
- Address
- 1250 PAGE MILL ROAD, PALO ALTO, CA, 94304
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-23 | M · Form 4 | 20,000 | A | 2.35 | 20,000 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 2.35 | 2026-10-23 | M · Form 4 | 20,000 | D | 0 | [F1] | 2034-06-28 | Common Stock | 20,000 | 20,000 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- Shares subject to the option are fully vested.↩ 1
Signature 1
- Signed
- /s/ David Peinsipp, Attorney-in-Fact for Taiyin Yang
- Date
- 2026-10-26
Company context
Kodiak Sciences (Nasdaq: KOD) is a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next-generation retinal medicines to prevent and treat the leading causes of blindness globally. We are developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in wet AMD, diabetic retinopathy, and retinal vein occlusion. KSI-501 is being evaluated in wet AMD and diabetic macular edema. Zenkuda and KSI-501 target the $15 billion anti-VEGF market across retinal vascular diseases. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Topline data for Pivotal Analysis 1 (PEAK) are expected in December 2026 and Pivotal Analysis 2 (PEAK+PINNACLE) in 2Q 2027.